GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS-Reference-Cited by-同舟云学术

GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS

Published:2017-06 Issue: Volume:35 Page:27-27
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Schuster S.J.¹,Bishop M.R.²,Tam C.³,Waller E.K.⁴,Borchmann P.⁵,Mcguirk J.⁶,Jäger U.⁷,Jaglowski S.⁸,Andreadis C.⁹,Westin J.¹⁰,Fleury I.¹¹,Bachanova V.¹²,Foley S.R.¹³,Ho P.J.¹⁴,Mielke S.¹⁵,Holte H.¹⁶,Anak O.¹⁷,Pacaud L.¹⁷,Awasthi R.¹⁸,Tai F.¹⁹,Salles G.²⁰,Maziarz R.²¹

Affiliation:

1. Lymphoma Program, Abramson Cancer Center; University of Pennsylvania; Philadelphia USA

2. Hematopoietic Cellular Therapy Program; The University of Chicago Medicine; Chicago USA

3. Division of Hematology and Oncology; Peter MacCallum Cancer Centre; Melbourne Australia

4. Department of Hematology and Medical Oncology; Emory University School of Medicine; Atlanta USA

5. Department of Internal Medicine; University Hospital of Cologne; Cologne Germany

6. Department of Blood and Bone Marrow Transplant; The University of Kansas Cancer Center; Kansas City USA

7. Department of Medicine I, Division of Hematology and Hemostaseology; Medical University of Vienna; Vienna Austria

8. Department of Internal Medicine; The Ohio State University Wexner Medical Center; Columbus USA

9. Helen Diller Family Comprehensive Cancer Center; University of California San Francisco Medical Center; San Francisco USA

10. Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA

11. Department of Medicine, University of Montreal; Maisonneuve-Rosemont Hospital CIUSSS East; Montreal Canada

12. Department of Medicine; University of Minnesota; Minneapolis USA

13. Department of Medicine; McMaster University; Hamilton Canada

14. Institute of Haematology; Royal Prince Alfred Hospital & Sydney University; Sydney Australia

15. Medizinische Klinik und Poliklinik II; Universitatsklinikum Würzburg; Würzburg Germany

16. Department of Oncology; Oslo University Hospital; Oslo Norway

17. Global Drug Development; Novartis Pharma AG; Basel Switzerland

18. PK Sciences; Novartis Pharmaceuticals Corporation; East Hanover USA

19. Biostatistics; Novartis Pharmaceuticals Corporation; East Hanover USA

20. Hospices Civils de Lyon; Université de Lyon; Lyon France

21. Center for Hematologic Malignancies, Knight Cancer Institute; Oregon Health & Science University; Portland USA

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells;Journal of Biomedical Science;2023-05-31

2. Oncologic Emergencies;Holland‐Frei Cancer Medicine;2022-10-21

3. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments;Frontiers in Immunology;2022-07-22

4. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma;Cochrane Database of Systematic Reviews;2021-09-13

5. Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?;Cureus;2021-07-10